Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN), a Phase 3 clinical-stage neuropsychiatry company, today announced that its Chief Medical Officer, Amir Inamdar, will participate in a panel discussion at the 2025 Milken Institute Future of Health Summit, taking place Nov. 4–6, 2025, in Washington, D.C. The summit brings together leaders from across the health sector to discuss innovations and policies shaping the future of health. Inamdar's presence underscores Cybin's growing prominence as it advances its lead candidate, CYB003, through late-stage clinical trials for major depressive disorder (MDD).
Cybin is developing CYB003, a proprietary deuterated psilocin analog, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. The company is currently conducting Phase 3 studies for CYB003 as an adjunctive treatment for MDD, a condition affecting millions worldwide. If approved, CYB003 could offer a novel therapeutic option for patients who do not respond adequately to existing antidepressants. Inamdar's participation at the Milken Institute summit provides a platform to discuss the potential of psychedelic-based treatments to address the large unmet need in mental health care.
The company also has a pipeline of other investigational compounds. CYB004, a proprietary deuterated N,N-dimethyltryptamine molecule, is in Phase 2 studies for generalized anxiety disorder. Additionally, Cybin is exploring other 5-HT-receptor focused compounds in its research pipeline. Founded in 2019, Cybin operates in Canada, the United States, the United Kingdom and Ireland. The company's commitment to developing next-generation treatment options aims to provide effective and durable results for patients suffering from mental health conditions. For more details on the press release, visit https://ibn.fm/8AL6L.
The Milken Institute Future of Health Summit is a key event for stakeholders in healthcare innovation. Inamdar's inclusion on a panel signals that Cybin's work is gaining recognition among policy makers and industry leaders. As the company progresses toward potential regulatory submissions, its engagement at such forums may help shape the conversation around the integration of psychedelic therapies into mainstream medicine. Investors and followers can find the latest news and updates on Cybin at the company's newsroom: https://ibn.fm/CYBN.
